The Institute for Clinical and Economic Review (ICER) on Friday, June 7, announced plans to assess the comparative clinical effectiveness and value of acute migraine treatments.
According to a press release, the organization will review Biohaven’s rimegepant, Allergan’s ubrogepant and Eli Lilly’s lasmiditan. The Food and Drug Administration is expected to decide on the drugs at the end of the year.
ICER is accepting public input on the development of the evidence report until 5 p.m. EST June 25.
A draft scoping document is set to be published June 28.
To read the full press release, click here.